The Latest Headlines at American Banking and Market News
CDW (NASDAQ:CDW) PT Lowered to $265.00 at JPMorgan Chase & Co.
CDW (NASDAQ:CDW – Free Report) had its price objective cut by JPMorgan Chase & Co. from $280.00 to $265.00 in a research note released on Thursday morning, Benzinga reports. They currently have an overweight rating on the... More of this article »
HC Wainwright Reaffirms “Buy” Rating for Biomea Fusion (NASDAQ:BMEA)
HC Wainwright reissued their buy rating on shares of Biomea Fusion (NASDAQ:BMEA – Free Report) in a report released on Friday morning, Benzinga reports. The firm currently has a $50.00 target price on the stock. BMEA has been... More of this article »
Barclays Cuts CDW (NASDAQ:CDW) Price Target to $232.00
CDW (NASDAQ:CDW – Free Report) had its price target cut by Barclays from $261.00 to $232.00 in a research note released on Thursday morning, Benzinga reports. They currently have an equal weight rating on the information technology... More of this article »
TG Therapeutics (NASDAQ:TGTX) PT Raised to $49.00
TG Therapeutics (NASDAQ:TGTX – Free Report) had its price target boosted by HC Wainwright from $45.00 to $49.00 in a report released on Thursday, Benzinga reports. The firm currently has a buy rating on the biopharmaceutical... More of this article »
Barclays Boosts Blueprint Medicines (NASDAQ:BPMC) Price Target to $75.00
Blueprint Medicines (NASDAQ:BPMC – Free Report) had its price objective lifted by Barclays from $70.00 to $75.00 in a research report released on Friday morning, Benzinga reports. The firm currently has an equal weight rating... More of this article »
Blueprint Medicines (NASDAQ:BPMC) Price Target Raised to $135.00
Blueprint Medicines (NASDAQ:BPMC – Free Report) had its price objective raised by HC Wainwright from $125.00 to $135.00 in a report published on Friday, Benzinga reports. They currently have a buy rating on the biotechnology... More of this article »
Blueprint Medicines (NASDAQ:BPMC) Upgraded at StockNews.com
StockNews.com upgraded shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) from a sell rating to a hold rating in a research note released on Friday. BPMC has been the topic of a number of other reports. Piper Sandler upped... More of this article »
New York State Common Retirement Fund Decreases Stock Position in AXIS Capital Holdings Limited (NYSE:AXS)
New York State Common Retirement Fund trimmed its holdings in shares of AXIS Capital Holdings Limited (NYSE:AXS – Free Report) by 50.6% during the 4th quarter, according to the company in its most recent filing with the Securities... More of this article »
Citigroup Boosts Blueprint Medicines (NASDAQ:BPMC) Price Target to $76.00
Blueprint Medicines (NASDAQ:BPMC – Free Report) had its price target increased by Citigroup from $65.00 to $76.00 in a report issued on Friday, Benzinga reports. The brokerage currently has a sell rating on the biotechnology... More of this article »
AtriCure (NASDAQ:ATRC) Price Target Cut to $49.00 by Analysts at Canaccord Genuity Group
AtriCure (NASDAQ:ATRC – Free Report) had its price objective decreased by Canaccord Genuity Group from $57.00 to $49.00 in a research note published on Thursday morning, Benzinga reports. Canaccord Genuity Group currently has... More of this article »
Barrett Business Services (NASDAQ:BBSI) Rating Increased to Strong-Buy at StockNews.com
StockNews.com upgraded shares of Barrett Business Services (NASDAQ:BBSI – Free Report) from a buy rating to a strong-buy rating in a research note issued to investors on Thursday. Separately, Barrington Research reissued an... More of this article »
Booking’s (BKNG) “Hold” Rating Reiterated at Benchmark
Benchmark restated their hold rating on shares of Booking (NASDAQ:BKNG – Free Report) in a report published on Friday, Benzinga reports. A number of other brokerages have also weighed in on BKNG. Evercore ISI raised their price... More of this article »
Booking (NASDAQ:BKNG) Earns Outperform Rating from BMO Capital Markets
BMO Capital Markets reissued their outperform rating on shares of Booking (NASDAQ:BKNG – Free Report) in a report issued on Friday, Benzinga reports. They currently have a $4,205.00 price target on the business services provider’s... More of this article »